Theranos Investors Can’t Delay Class Action-Ending Deal

A California federal judge refused Friday to push back a deadline for Theranos shareholders to agree to a deal that would resolve class allegations the company misled investors about the accuracy of its blood tests, finding that notices from the beleaguered startup disclosing terms of the deal aren’t coercive or misleading.